drugset / Trial / NCT00614354
Study of 99mTc-glucarate to Detect Acute Coronary Syndrome in Chest Pain Patients.
Phase 2
Completed
66 enrolled
Molecular Targeting Technologies, Inc.
National Heart, Lung, and Blood Institute (NHLBI) · collabUniversity Hospitals Cleveland Medical Center · collabUniversity of Alabama at Birmingham · collabUniversity of Pittsburgh · collabYale University · collab
NaSingle-groupOpen-labelDiagnostic
Summary
The purpose of this clinical trial is to study the ability of a radioactive drug called "Technetium Glucarate" to detect whether the cause of chest pain in patients entering the emergency department with no obvious signs of heart attack is due to a condition called Acute Coronary Syndrome (ACS). The drug will be injected intravenously. After one or two hours the patient will undergo an imaging procedure to detect if the drug has accumulated in the heart. Uptake of the radioactive drug in the heart is indicative of reduced blood flow to the heart.
Timeline
- Start
- 2008-10
- Primary completion
- 2010-09
- Completion
- 2010-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 99mTc-glucarate | Diagnostic / imaging agent | 814 mbq | Intravenous |
| Subject | 99mTc-glucarate | Diagnostic / imaging agent | 999 mbq | Intravenous |